SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gets USFDA’s tentative approval for DETAF Tablets

31 Jan 2023 Evaluate

Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets. This product would be manufactured at Lupin’s Nagpur facility in India. DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- & middle-income countries.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2466.30 67.60 (2.82%)
03-Jul-2026 12:40 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1909.15
Dr. Reddys Labs. 1379.50
Cipla 1459.40
Zydus Lifesciences 1133.00
Lupin 2466.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: